More for AtCor
Thursday, 24 July, 2008
AtCor Medical [ASX: ACG] has reached new supply agreements for its SphygmoCor blood-pressure measurement systems.
The contracts are worth at least a combined $1.66 million. AtCor has secured $2.8 million worth of contracts in the past 60 days.
SphygmoCor is a blood pressure monitoring system that identifies the effects of reflected blood pressure in the central aortic pressure wave.
The company has sold over 1,400 SphygmoCors to medical institutions and research institutions conducting clinical trials, as the device can be used to measure the effects of medication on central blood pressure.
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
